Search

Displaying results 4011 - 4020 of 4359 in total
  1. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.

  2. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.

  3. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    As of May 2015, it is in phase III clinical trials for schizophrenia.

  4. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treat...

  5. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  6. Drug

    Dutogliptin

    go.drugbank.com/drugs/DB11723
    Investigational

    Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.

  7. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial grow...

  8. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes. Zinc chloride was granted FDA approval before 26 June 1986.

  9. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as

  10. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653]. … The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the